Latest Regulatory News

Astron Corporation has responded to ASX concerns over a delayed Appendix 3Y filing, attributing the lag to director travel and reaffirming its compliance protocols.

InhaleRx has corrected its quarterly report and revealed a $38.5 million funding deal to fast-track clinical trials for its inhaled therapies targeting breakthrough cancer pain and panic disorder, aiming for FDA approval.

K-TIG Limited is set to transform its business with a $7–10 million capital raise to acquire US-based Metal Powder Works, issuing performance-based vendor shares that an independent expert deems fair and reasonable.

8VI Holdings Limited has confirmed its voluntary delisting from the ASX, reporting a challenging quarter marked by declining cash reserves and a strategic pivot towards preventive care that is yet to yield significant revenue.

360 Capital Group has announced a fully franked dividend of AUD 0.02 per security for the six months ending December 31, 2024, payable on January 24, 2025. This update confirms the payment details and clarifies the distribution source.

Patagonia Lithium has withdrawn its previously announced 15-year, 10,000 tonnes per annum production target, clarifying it was aspirational and not compliant with ASX Listing Rules. This retraction raises questions about the project's near-term viability and investor confidence.

Kali Metals Limited has acknowledged a delay in lodging director interest notices due to an administrative oversight, reaffirming its commitment to ASX compliance and outlining existing disclosure procedures.

Arafura Rare Earths Limited has acknowledged a breach of ASX Listing Rule 15.7 following premature media disclosure of a $200 million investment commitment from the National Reconstruction Fund Corporation. The company outlines corrective steps to prevent future compliance lapses.

Entyr Limited has launched a $9.5 million capital raising via a Share Purchase Plan and Placement Offer, aiming to recapitalize and return to ASX trading following its recent voluntary administration.

Alterity Therapeutics is poised to release topline data from its pivotal ATH434-201 Phase 2 trial in early-stage Multiple System Atrophy by February 2025, while managing a cash balance of A$4.54 million amid ongoing research expenses.

Meeka Metals has responded to an ASX query regarding the timing and nature of its recent cleansing notice, confirming that the drilling results reinforce existing mineral resources without revealing new discoveries.

African Gold Ltd. has temporarily paused trading of its securities, signaling a potentially significant update on the horizon. Investors await clarity on what this development might mean for the gold miner’s future.